Zentek Ltd. announced that its wholly-owned subsidiary, Triera Biosciences Ltd., has been awarded a $1.1 million contract from the Government of Canada. This contract is designated for the testing of its Multivalent Aptamer Technology.
The funding provides significant non-dilutive capital to advance the development and validation of this proprietary technology.
This contract represents a key milestone, offering external validation and financial support for Zentek's innovative biomedical research initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.